6.14
Schlusskurs vom Vortag:
$5.29
Offen:
$5.3
24-Stunden-Volumen:
6.75M
Relative Volume:
2.97
Marktkapitalisierung:
$337.39M
Einnahmen:
$3.64M
Nettoeinkommen (Verlust:
$-87.37M
KGV:
-1.4939
EPS:
-4.11
Netto-Cashflow:
$-86.46M
1W Leistung:
+18.99%
1M Leistung:
+42.79%
6M Leistung:
+3.72%
1J Leistung:
+106.73%
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Vergleichen Sie VSTM mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VSTM
Verastem Inc
|
6.14 | 290.68M | 3.64M | -87.37M | -86.46M | -4.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-10 | Eingeleitet | Jefferies | Buy |
2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
2024-12-31 | Bestätigt | BTIG Research | Buy |
2024-09-30 | Eingeleitet | Guggenheim | Buy |
2023-11-21 | Fortgesetzt | BTIG Research | Buy |
2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
2022-03-09 | Eingeleitet | Truist | Buy |
2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2018-07-13 | Eingeleitet | BTIG Research | Buy |
2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
2015-05-12 | Bestätigt | UBS | Buy |
2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
2015-01-23 | Bestätigt | ROTH Capital | Buy |
2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
What drives Verastem Inc. stock priceUnstoppable profit momentum - PrintWeekIndia
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Pancreatic Cancer - Targeted Oncology
Verastem Inc. Stock Analysis and ForecastRapid capital growth - PrintWeekIndia
What analysts say about Verastem Inc. stockFree Market Dynamics Reports - Autocar Professional
Is Verastem Inc. a good long term investmentAccelerated earnings growth - Autocar Professional
Verastem’s Phase 3 Study Update: A Potential Game-Changer in Ovarian Cancer Treatment - TipRanks
Verastem's Fast-Track KRAS G12D Inhibitor: A Strategic Play in a High-Unmet-Need Oncology Market - AInvest
Verastem Oncology gets FDA fast track status for cancer drug - Seeking Alpha
Verastem Oncology’s VS-7375 Granted Fast Track Designation by the FDA - Contract Pharma
FDA grants fast track designation to Verastem’s pancreatic cancer drug By Investing.com - Investing.com Canada
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer - Yahoo Finance
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
(VSTM) Proactive Strategies - news.stocktradersdaily.com
Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha
Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance
Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest
Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada
Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com
Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Verastem Inc-Aktie (VSTM) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Calkins Daniel | Chief Financial Officer |
Jun 20 '25 |
Sale |
5.13 |
4,110 |
21,084 |
109,945 |
Calkins Daniel | Chief Financial Officer |
Jun 23 '25 |
Sale |
4.71 |
25 |
118 |
109,920 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):